Financials data is unavailable for this security.
View more
Year on year Ligand Pharmaceuticals Inc had revenues fall -33.09% from 196.25m to 131.31m, though the company grew net income from a loss of 33.36m to a gain of 52.15m.
| Gross margin | 91.82% |
|---|---|
| Net profit margin | 31.57% |
| Operating margin | -14.53% |
| Return on assets | 5.19% |
|---|---|
| Return on equity | 5.85% |
| Return on investment | 5.35% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Ligand Pharmaceuticals Inc fell by 22.05m. However, the company earned 49.58m from its operations for a Cash Flow Margin of 37.75%. In addition the company used 11.68m on investing activities and also paid 59.95m in financing cash flows.
| Cash flow per share | 4.24 |
|---|---|
| Price/Cash flow per share | 28.66 |
| Book value per share | 42.82 |
|---|---|
| Tangible book value per share | 16.92 |
More ▼
Balance sheet in USDView more
| Current ratio | 16.82 |
|---|---|
| Quick ratio | 15.81 |
| Total debt/total equity | 0.00002 |
|---|---|
| Total debt/total capital | 0.00002 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 1,079.59%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | -12.71 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -40.66 |
